FDA approves Pfizer's Besponsa in aggressive blood cancer

07:43 EDT 18 Aug 2017 | pharmaphorum

US regulators have approved Pfizer’s new drug, Besponsa, offering a new option for patients with a rare and aggressive form of blood cancer. Besponsa (inotuzumab ozogamicin) is the first of its kind to be indicated for adults with relapsed or re...

Original Article: FDA approves Pfizer's Besponsa in aggressive blood cancer


More From BioPortfolio on "FDA approves Pfizer's Besponsa in aggressive blood cancer"

Quick Search


Relevant Topics

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...